Literature DB >> 22461374

Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.

Gerben Duns1, Robert M W Hofstra, Jantine G Sietzema, Harry Hollema, Inge van Duivenbode, Angela Kuik, Cor Giezen, Osinga Jan, Jelkje J Bergsma, Harrie Bijnen, Pieter van der Vlies, Eva van den Berg, Klaas Kok.   

Abstract

Clear cell renal cell carcinomas are characterized by 3p loss, and by inactivation of Von Hippel Lindau (VHL), a tumorsuppressor gene located at 3p25. Recently, SETD2, located at 3p21, was identified as a new candidate ccRCC tumor-suppressor gene. The combined mutational frequency in ccRCC tumors of VHL and SETD2 suggests that there are still undiscovered tumor-suppressor genes on 3p. We screened all genes on 3p for mutations in 10 primary ccRCC tumors using exome-sequencing. We identified inactivating mutations in VHL, PBRM1, and BAP1. Sequencing of PBRM1 in ccRCC-derived cell lines confirmed its frequent inactivation in ccRCC. PBRM1 encodes for BAF180, the chromatin targeting subunit of the SWI/SNF complex. BAP1 encodes for BRCA1 associated protein-1, involved in histone deubiquitination. Taken together, the accumulating data suggest an important role for aberrant chromatin regulation in ccRCC development.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22461374     DOI: 10.1002/humu.22090

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  31 in total

1.  Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-/- clear cell renal carcinoma.

Authors:  Wenhua Gao; Wei Li; Tengfei Xiao; Xiaole Shirley Liu; William G Kaelin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-12       Impact factor: 11.205

3.  Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer.

Authors:  Moubin Lin; Liren Zhang; Michelle A T Hildebrandt; Maosheng Huang; Xifeng Wu; Yuanqing Ye
Journal:  Oncotarget       Date:  2017-08-24

Review 4.  SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.

Authors:  Catherine C Fahey; Ian J Davis
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

5.  NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Authors:  Roshan J Thapa; Peirong Chen; Mitchell Cheung; Shoko Nogusa; Jianming Pei; Suraj Peri; Joseph R Testa; Siddharth Balachandran
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

6.  HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Authors:  Abhishek A Chakraborty; Eijiro Nakamura; Jun Qi; Amanda Creech; Jacob D Jaffe; Joshiawa Paulk; Jesse S Novak; Kshithija Nagulapalli; Samuel K McBrayer; Glenn S Cowley; Javier Pineda; Jiaxi Song; Yaoyu E Wang; Steven A Carr; David E Root; Sabina Signoretti; James E Bradner; William G Kaelin
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

Review 7.  SWI/SNF chromatin remodeling complexes and cancer.

Authors:  Jaclyn A Biegel; Tracy M Busse; Bernard E Weissman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

8.  Prognostic role of BAP1 in pT1 clear cell carcinoma in partial nephrectomy specimens.

Authors:  Daniele Minardi; Guendalina Lucarini; Giulio Milanese; Rodolfo Montironi; Roberto Di Primio
Journal:  Virchows Arch       Date:  2017-05-09       Impact factor: 4.064

Review 9.  Metabolism of kidney cancer: from the lab to clinical practice.

Authors:  Sunil Sudarshan; Jose A Karam; James Brugarolas; R Houston Thompson; Robert Uzzo; Brian Rini; Vitaly Margulis; Jean-Jacques Patard; Bernard Escudier; W Marston Linehan
Journal:  Eur Urol       Date:  2012-09-28       Impact factor: 20.096

Review 10.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.